Neural Defect Tower

The neural defect tower is the τ-categorical 4-level hierarchical structure of defect accumulation on the neural τ³-computer (VI.D52). It is not a metaphor — it is the structural specialization of the aging defect functional (VI.D43) to the nervous system, with one monotonically non-decreasing defect functional Δ_i(n) at each of four levels (molecular, synaptic, circuit, network) and an unidirectional upward cascade (VI.T52).

Categorical invariant. 4-level monotone tower of defect functionals on the neural τ³-computer, each Δ_i specializing the universal aging defect functional VI.D43 to one structural stratum, coupled by threshold-triggered upward cascade (VI.T52). The tower is total: Δ_neural(n) = Σ Δ_i(n) is monotonically non-decreasing in the refinement step n.

Primary registry anchor: VI.D88

Supporting items: VI.D87, VI.D52, VI.D43, VI.T52, VI.P23

1. I.K0 — Universe Postulate
2. VI.D15 — Life Sector
3. VI.D43 — Aging as Defect Accumulation — universal monotone defect functional
4. VI.D52 — Neural Architecture as τ³ Computer
5. VI.D87 — Neural Defect Level — four hierarchical levels (molecular/synaptic/circuit/network)
6. VI.D88 — Neural Defect Tower — the 4-level monotone structure on VI.D52
7. VI.T52 — Inter-Level Cascade — upward-only threshold-triggered acceleration

Biomarker: Level 1 (molecular): amyloid-β plaques, hyperphosphorylated tau, α-synuclein aggregates, oxidative DNA/lipid damage. Level 2 (synaptic): synapse density loss, neurotransmitter depletion, receptor downregulation. Level 3 (circuit): pathway-specific neuronal loss (dopaminergic, cholinergic, motor). Level 4 (network): white-matter degeneration, decreased global connectomic efficiency.

Measurable range: Normal aging: all four Δ_i monotonically increase, none crosses cascade threshold θ_i before organismal Hayflick limit. Disease: dominant level identifies diagnosis — Alzheimer's (Level 1), Parkinson's/ALS (Level 3), Huntington's (Level 1). Synapse loss in healthy aging: ~0.5–1% per decade in cortex; in Alzheimer's: 30–50% in affected regions.

Observation method: Level 1: PET amyloid/tau imaging, CSF Aβ42/tau ratios, post-mortem histopathology. Level 2: synaptic density via PET ligand UCB-J (SV2A), electron microscopy. Level 3: DAT-SPECT (dopaminergic), structural MRI volumetry. Level 4: diffusion tensor imaging (DTI), connectomics, fMRI default-mode network analysis.

Calibration anchor: LG-Y02-kinetic-pseudoscalar-channel

Anchor chain:

1. VI.L18 chirality channel
2. L-amino-acid neurotransmitter / receptor stereospecificity at every tower level
3. stereochemically biased misfolding (amyloid-β, tau, α-synuclein) inheriting the L-handed chiral substrate

Manuscript reference: manuscript-sources/book-06/part06/ch40-neural-systems.tex

Status: Planned

Related glossary entries

• LG-M01-consciousness Consciousness
• LG-M03-sleep-repair Sleep Repair Function
• LG-M08-neural-hayflick-bound Neural Hayflick Bound
• LG-Y02-kinetic-pseudoscalar-channel Kinetic Pseudoscalar Channel

Referenced by

• LG-M03-sleep-repair Sleep Repair Function
• LG-M08-neural-hayflick-bound Neural Hayflick Bound